Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]

  • Mingming Sun
  • , Leilei Li
  • , Yujia Niu
  • , Yingzhi Wang
  • , Qi Yan
  • , Fei Xie
  • , Yaya Qiao
  • , Jiaqi Song
  • , Huanran Sun
  • , Zhen Li
  • , Sizhen Lai
  • , Hongkai Chang
  • , Han Zhang
  • , Jiyan Wang
  • , Chenxin Yang
  • , Huifang Zhao
  • , Junzhen Tan
  • , Yanping Li
  • , Shuangping Liu
  • , Bin Lu
  • Min Liu, Guangyao Kong, Yujun Zhao, Chunze Zhang, Shu Hai Lin, Cheng Luo, Shuai Zhang, Changliang Shan

Research output: Contribution to journalComment/debate

Abstract

The authors regret that a mistake occurred during the presentation of Supporting Information Fig. S1B, in which we put the wrong picture during submission. This correction does not significantly impact the findings and conclusions of the paper. The authors would like to assure readers that the corrected image does not alter the validity of the research. The original data of these figures have been provided to the Editorial Office, and the corresponding author can be contacted for original data access. The authors would like to apologize for any inconvenience caused. The corrected Fig. S1B appears below.[Figure

Original languageEnglish
Pages (from-to)2297-2299
Number of pages3
JournalActa Pharmaceutica Sinica B
Volume15
Issue number4
DOIs
StatePublished - Apr 2025
Externally publishedYes

Fingerprint

Dive into the research topics of 'Erratum: Author correction to “PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism” [Acta Pharm Sin B 13 (2023) 157–173, (S2211383522002416), (10.1016/j.apsb.2022.05.019)]'. Together they form a unique fingerprint.

Cite this